Back to results
US 9,957,507 B2Granted
Compositions and methods for inhibiting expression of mutant EGFR gene
AssigneesAlnylam Pharmaceuticals, Inc., Ludwig Institute for Cancer Research
InventorsDinah Sah, Pamela Tan, Webster Cavenee, Frank Furnari, Maria del Mar Inda Perez, Rudy Bonavia
Life of this patent
Estimating the term…
Abstract
The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a mutant Epidermal Growth Factor Receptor (EGFR), and methods of using the dsRNA to inhibit expression of mutant EGFR.
Claims25
A double-stranded ribonucleic acid (dsRNA), wherein said dsRNA is 15-30 nucleotides in length and comprises at least two sequences that are complementary to each other,
- wherein a sense strand comprises a first sequence comprising a nucleotide sequence chosen from SEQ ID NO:
- 8, SEQ ID NO:
- 10, SEQ ID NO:
- 12, SEQ ID NO:
- 16, SEQ ID NO:
- 54, SEQ ID NO:
- 56, SEQ ID NO;
- 58, SEQ ID NO:
- 60, or SEQ ID NO:
- 64, and
- wherein an antisense strand comprises a second sequence comprising a region of complementarity which is substantially complementary to at least a part of the first sequence, wherein the second sequence comprises a nucleotide sequence chosen from SEQ ID NO:
- 9, SEQ ID NO:
- 11, SEQ ID NO:
- 13, SEQ ID NO:
- 17, SEQ ID NO:
- 55, SEQ ID NO:
- 57, SEQ ID NO;
- 59, SEQ ID NO:
- 61, or SEQ ID NO:
- 65, and wherein said region of complementarity is 15-30 nucleotides in length.
17 more elements
Dependencies are inferred from the claim text.